132 related articles for article (PubMed ID: 11690567)
21. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulation and the cardioversion of atrial flutter.
James PR; Hardman SM
Int J Clin Pract; 2000; 54(1):5-6. PubMed ID: 10750250
[No Abstract] [Full Text] [Related]
23. Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis.
Wong BM; Perry JJ; Cheng W; Zheng B; Guo K; Taljaard M; Skanes AC; Stiell IG
CJEM; 2021 Jul; 23(4):500-511. PubMed ID: 33715143
[TBL] [Abstract][Full Text] [Related]
24. [Predictive factors of maintenance of sinus rhythm after direct current (DC) cardioversion of atrial fibrillation/atrial flutter].
Larsen MT; Lyngborg K; Pedersen F; Corell P
Ugeskr Laeger; 2005 Sep; 167(36):3408-12. PubMed ID: 16159494
[TBL] [Abstract][Full Text] [Related]
25. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Yadlapati A; Groh C; Passman R
Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
[TBL] [Abstract][Full Text] [Related]
26. Patients undergoing cardioversion of atrial flutter should be routinely anticoagulated.
Densèm CG
Am J Cardiol; 1999 Jan; 83(1):140-1. PubMed ID: 10073808
[No Abstract] [Full Text] [Related]
27. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
[TBL] [Abstract][Full Text] [Related]
28. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin.
Frederiksen AS; Albertsen AE; Christesen AMS; Vinter N; Frost L; Møller DS
Europace; 2018 Jul; 20(7):1078-1085. PubMed ID: 28655151
[TBL] [Abstract][Full Text] [Related]
29. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion.
Roijer A; Eskilsson J; Olsson B
Eur Heart J; 2000 May; 21(10):837-47. PubMed ID: 10781356
[TBL] [Abstract][Full Text] [Related]
30. Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion.
Själander S; Svensson PJ; Friberg L
Int J Cardiol; 2016 Jul; 215():360-3. PubMed ID: 27128562
[TBL] [Abstract][Full Text] [Related]
31. Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure.
Brandes A; Crijns HJGM; Rienstra M; Kirchhof P; Grove EL; Pedersen KB; Van Gelder IC
Europace; 2020 Aug; 22(8):1149-1161. PubMed ID: 32337542
[TBL] [Abstract][Full Text] [Related]
32. [Systemic embolism after reversion to sinusal rhythm of persistent atrial flutter].
Hernández Madrid A; Peña Pérez G; González Rebollo JM; Gómez Bueno M; Marín Marín I; Bernal Morell E; Escobar Cervantes C; Camino López A; Peng J; Moro Serrano C
Rev Clin Esp; 2003 May; 203(5):230-5. PubMed ID: 12765569
[TBL] [Abstract][Full Text] [Related]
33. Cerebral thromboembolism after direct current cardioversion for pure atrial flutter.
Liaudet L; Kehtari R; Enrico JF
Intensive Care Med; 1997 Feb; 23(2):196-7. PubMed ID: 9069005
[TBL] [Abstract][Full Text] [Related]
34. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
Femia G; Fetahovic T; Shetty P; Lee A
Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
[TBL] [Abstract][Full Text] [Related]
35. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials.
Moreyra E; Finkelhor RS; Cebul RD
Am Heart J; 1995 Jan; 129(1):71-5. PubMed ID: 7817928
[TBL] [Abstract][Full Text] [Related]
36. Intensity of anticoagulation and risk of thromboembolism after elective cardioversion of atrial fibrillation.
Hellman T; Kiviniemi T; Nuotio I; Vasankari T; Hartikainen J; Lip GYH; Airaksinen KEJ
Thromb Res; 2017 Aug; 156():163-167. PubMed ID: 28662483
[TBL] [Abstract][Full Text] [Related]
37. Cardioversion of atrial tachyarrhythmias: anticoagulation to reduce thromboembolic complications.
Guo H; Shaheen W; Kerber R; Olshansky B
Prog Cardiovasc Dis; 2004; 46(6):487-505. PubMed ID: 15224256
[No Abstract] [Full Text] [Related]
38. Early cardioversion of atrial fibrillation and atrial flutter guided by transoesophageal echocardiography: a single centre 8.5-year experience.
Corrado G; Santarone M; Beretta S; Tadeo G; Tagliagambe LM; Foglia-Manzillo G; Spata M; Miglierina E; Acquati F; Santarone M
Europace; 2000 Apr; 2(2):119-26. PubMed ID: 11225938
[TBL] [Abstract][Full Text] [Related]
39. The Risk of Thromboembolic Complications in Fontan Patients with Atrial Flutter/Fibrillation Treated with Electrical Cardioversion.
Lin JH; Kean AC; Cordes TM
Pediatr Cardiol; 2016 Oct; 37(7):1351-60. PubMed ID: 27421846
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
